LRRK2-IN-17

LRRK2-IN-17 (Compound 6) is an orally active LRRK2 inhibitor (IC50: 3.5 and 3.3 nM for WT and G2019S, respectively) . LRRK2-IN-17 inhibits RET kinase (IC50: 59 nM) . LRRK2-IN-17 can be used in cancer and Parkinson's disease (PD) research[1].

Product Specifications

CAS Number

[2101821-86-5]

UNSPSC

12352005

Target

LRRK2; RET

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Smiles

CN1C=C(NC2=NC(N[C@@H]3C4=C(C=CC=C4)CC3)=C5C=CNC5=N2)N=N1

Molecular Formula

C18H18N8

Molecular Weight

346.39

References & Citations

[1]Moukha-Chafiq O, et al. Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3-d]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor. J Med Chem. 2025 May 22;68 (10) :9926-9946.